Porton Biopharma staff will be attending and presenting at a number of international conferences this autumn and we would be delighted to speak to you about our capabilities.
In a ribbon cutting ceremony, John Glen MP for Salisbury and South Wiltshire today (27th April 2018) officially opened Porton Biopharma Limited’s (PBL) new fermentation facility which will be used to manufacture the company’s life-saving leukaemia drug Erwinase®.
UK biotech to manufacture novel medicines for Inflammatory Bowel Disease using spores of gut bacteria
PBL are one of three leading British biotechnology businesses have obtained grant funding from Innovate UK to investigate the manufacture of a new class of medicines, targeting a range of clinical conditions through interaction with the human microbiome.
We are pleased to announce that we will be attending Bioprocessing Summit Europe from 20-22 March in Lisbon. Do come and visit us at Stand No 14 and also see our poster on “A QbD approach to Developing Protein Therapeutics”. We are also able to offer a discount code of up to $200 for our contacts who wish to register and attend the event.
Porton Biopharma is pleased to be the official sponsor at the Royal Society of Biology’s President’s Dinner. Following the Society’s Annual General Meeting on 2 May in London, the dinner celebrates Professor Dame Julia Goodfellow DBE CBE CBiol FRSB succeeding Professor Dame Jean Thomas FRS FMedSci Hon FRSB.
PBL staff will be attending and presenting some of our lastest science at a number of International scientific and business conferences this autumn.
Click the link for more information
Porton Biopharma Limited (PBL) has officially opened and named their new multi-million pound pharmaceutical laboratories with a ribbon cutting ceremony lead by Baroness Jane Scott of Bybrook OBE, Leader of Wiltshire Council. The facility has been named the Atkinson Development Centre (or ADC) in tribute to Professor Tony Atkinson
Porton Biopharma Ltd (PBL) has today announced that it has signed a modification to its contract with the US National Institute of Health’s National Institute of Allergy and Infectious Diseases (NIAID) to advance a next generation intra-nasal anthrax vaccine. The contract modification is worth US$5.6 million.